CA2720396A1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
CA2720396A1
CA2720396A1 CA2720396A CA2720396A CA2720396A1 CA 2720396 A1 CA2720396 A1 CA 2720396A1 CA 2720396 A CA2720396 A CA 2720396A CA 2720396 A CA2720396 A CA 2720396A CA 2720396 A1 CA2720396 A1 CA 2720396A1
Authority
CA
Canada
Prior art keywords
modulator
complex
enzyme
pdh
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2720396A
Other languages
English (en)
French (fr)
Inventor
Robert Shorr
Paul Bingham
Lakmal W. Boteju
Zuzana Zachar
Robert Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2720396A1 publication Critical patent/CA2720396A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2720396A 2008-04-04 2008-04-04 Pharmaceutical composition Abandoned CA2720396A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/004410 WO2009123597A1 (en) 2008-04-04 2008-04-04 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CA2720396A1 true CA2720396A1 (en) 2009-10-08

Family

ID=41135840

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2720396A Abandoned CA2720396A1 (en) 2008-04-04 2008-04-04 Pharmaceutical composition

Country Status (10)

Country Link
EP (1) EP2268278A4 (pt)
JP (1) JP2011516473A (pt)
KR (1) KR20110025168A (pt)
CN (1) CN102056605A (pt)
AU (1) AU2008354009A1 (pt)
BR (1) BRPI0821894A2 (pt)
CA (1) CA2720396A1 (pt)
IL (1) IL208387A0 (pt)
MX (1) MX2010010867A (pt)
WO (1) WO2009123597A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343847B (es) 2010-07-08 2016-11-24 Wrigley W M Jun Co Goma de mascar que contiene una base de goma de matriz de gelatina reticulada.
US9421234B2 (en) * 2011-05-20 2016-08-23 Nutramax Laboratories, Inc. Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
CA2863600A1 (en) * 2012-02-16 2013-08-22 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
CN105142643B (zh) * 2012-12-19 2021-09-03 基石医药公司 药物化合物
AU2014398232B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
WO2015195071A1 (en) 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
CN110590624B (zh) * 2019-09-26 2021-02-26 苏州富士莱医药股份有限公司 一种硫辛酸衍生物8-(乙基二硫基)-6-(苯基二硫基)辛酸的制备方法
WO2023012305A1 (en) * 2021-08-04 2023-02-09 Cytacoat Ab Disulfide compounds as medicaments

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853497A (en) * 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2789991A (en) * 1954-05-20 1957-04-23 American Cyanamid Co Substituted disulfones
JPS61198148A (ja) * 1985-01-29 1986-09-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
DK1624060T3 (da) * 1998-03-20 2012-04-10 Commw Scient Ind Res Org Kontrol af genekspression
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
US6331559B1 (en) * 1998-10-26 2001-12-18 The Research Foundation Of State University Of New York At Stony Brook Lipoic acid derivatives and their use in treatment of disease
DE19904794A1 (de) * 1999-02-05 2000-08-10 Biotechnolog Forschung Gmbh Verfahren zur Verbesserung des Primärstoffwechsels von Säugerzelllinien
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
US7108977B2 (en) * 2000-05-19 2006-09-19 Hoffmann-La Roche Inc. Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells
WO2006119355A2 (en) * 2005-05-03 2006-11-09 Albert Einstein College Of Medicine Of Yeshiva University Mammalian hypothalamic nutrient modulation of glucose metabolism
US20070077583A1 (en) * 2005-09-21 2007-04-05 Aurelium Biopharma, Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
JP5412423B2 (ja) * 2007-04-18 2014-02-12 コーナーストーン ファーマシューティカルズ，インコーポレーテッド リポ酸誘導体
AU2008242827B2 (en) * 2007-04-18 2014-06-05 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
BRPI0821176A2 (pt) * 2008-03-04 2015-10-06 Robert Rodriguez modulador do estado de fosforilação de pelo menos um complexo de enzimas, método para modular o complexo de pdh em um paciente que apresenta uma doença, condição, ou síndrome e método pra diagnosticar e predizer benefício em um paciente que apresenta sintomas de uma doença, condição, ou síndrome causada por uma alteração da estrutura e/ou da atividade do complexo de pdh

Also Published As

Publication number Publication date
EP2268278A4 (en) 2011-11-09
BRPI0821894A2 (pt) 2015-07-21
AU2008354009A1 (en) 2009-10-08
WO2009123597A1 (en) 2009-10-08
EP2268278A1 (en) 2011-01-05
JP2011516473A (ja) 2011-05-26
CN102056605A (zh) 2011-05-11
MX2010010867A (es) 2011-05-25
IL208387A0 (en) 2010-12-30
KR20110025168A (ko) 2011-03-09

Similar Documents

Publication Publication Date Title
US8552050B2 (en) Activators of pyruvate kinase M2 and methods of treating disease
CA2720396A1 (en) Pharmaceutical composition
ES2663789T3 (es) Compuesto de pirazol-amida y usos medicinales del mismo
Gan et al. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity
US9642874B2 (en) Compositions of selenoorganic compounds and methods of use thereof
CA2638735A1 (en) Methods to identify inhibitors of the unfolded protein response
Jin et al. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno [2, 3-d] pyrimidine scaffold
Lougiakis et al. Synthesis and pharmacological evaluation of novel adenine–hydrogen sulfide slow release hybrids designed as multitarget cardioprotective agents
CA2717511A1 (en) Modulation of enzymatic structure, activity, and/or expression level
CA2739250C (en) Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same
Li et al. Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
EP3189033B1 (en) Pharmaceutical compounds
US20140243401A1 (en) Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compound
Oh et al. Selective targeting of cancer cells using a hydrogen peroxide-activated Hsp90 inhibitor
CA2965898C (en) Fatty acid analogs
CA2895029A1 (en) Metal complexes of lipoic acid derivatives
US11773096B2 (en) Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same
Hatzivassiliou et al. Akt-directed metabolic alterations in cancer
Zhou et al. Structural Optimization of Marine Natural Product Pretrichodermamide B for the Treatment of Colon Cancer by Targeting the JAK/STAT3 Signaling Pathway
Hu Development of Membrane-Protein Interaction Modulators as Allosteric Drug Candidates
Lengauer Targeting glutamine metabolism and mitochondria via natural compounds in cancer: novel therapeutic strategies
KR101384349B1 (ko) 세린-팔미토일트랜스퍼라아제 활성 저해제를 유효성분으로 포함하는 항암용 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130403

FZDE Discontinued

Effective date: 20151008